基于免疫状态的III期乳腺癌多药化疗个体化
[Individualization of polychemotherapy for stage III breast cancer based on immunologic status].
作者信息
Sabala P I
出版信息
Vopr Onkol. 1984;30(11):44-8.
PMID:6516259
Abstract
Immunologic response was studied in 91 cases of stage III breast cancer who received a CFMVP polychemotherapy. 23 patients were given decaris for immunostimulation. All cases showed a significant decrease in cellular immunity. CFMVP-treated patients showing a decrease of 30% and more should receive 300 mg of decaris twice a week for 3 weeks.
摘要
对91例接受CFMVP联合化疗的III期乳腺癌患者的免疫反应进行了研究。23例患者给予迪卡菌进行免疫刺激。所有病例的细胞免疫均显著下降。CFMVP治疗后细胞免疫下降30%及以上的患者，应每周两次服用300毫克迪卡菌，共3周。
Zotero 插件